1. Home
  2. CNS vs GH Comparison

CNS vs GH Comparison

Compare CNS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$66.52

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$112.15

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNS
GH
Founded
1986
2011
Country
United States
United States
Employees
N/A
2021
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
13.2B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
CNS
GH
Price
$66.52
$112.15
Analyst Decision
Hold
Strong Buy
Analyst Count
2
21
Target Price
$72.50
$99.48
AVG Volume (30 Days)
287.7K
1.8M
Earning Date
01-21-2026
02-19-2026
Dividend Yield
3.83%
N/A
EPS Growth
18.87
N/A
EPS
3.19
N/A
Revenue
$552,096,000.00
$902,569,000.00
Revenue This Year
$8.24
$35.00
Revenue Next Year
$9.40
$26.80
P/E Ratio
$20.32
N/A
Revenue Growth
11.13
30.38
52 Week Low
$58.39
$33.75
52 Week High
$93.19
$112.43

Technical Indicators

Market Signals
Indicator
CNS
GH
Relative Strength Index (RSI) 65.26 70.14
Support Level $62.43 $97.31
Resistance Level $64.82 $104.75
Average True Range (ATR) 1.34 3.83
MACD 0.42 0.26
Stochastic Oscillator 95.59 99.25

Price Performance

Historical Comparison
CNS
GH

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: